Progressive Supranuclear Palsy Clinical Trials 2023

What are the top hospitals conducting progressive supranuclear palsy research?

Progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder that affects movement, balance, and cognition. Although there are limited clinical trials dedicated to this condition, several top hospitals are committed to advancing research and treatment options for PSP patients.

Leading the way is the prestigious Mayo Clinic in Rochester, which currently has two active progressive supranuclear palsy trials underway. With a total of four previous studies conducted since their first recorded trial in 2015, Mayo Clinic's dedication to understanding this complex disease is commendable.

In Boca Raton, Florida, both Dr. Stuart Isaacson and the Parkinson's disease and Movement Disorders Center share a common goal of finding answers through clinical trials. Dr. Isaacson initiated his first progressive supranuclear palsy trial just recently in 2021 while the center itself has been actively involved with one ongoing study as well as two prior investigations dating back to 2010.

Massachusetts General Hospital in Boston also contributes significantly to PSP research with its seven cumulative studies carried out since recording their initial trial in 2010. Currently conducting one active trial for progressive supranuclear palsy patients demonstrates their commitment towards furthering our understanding of this challenging condition.

Finally, at Quest Research Institute located in Farmington Hills, Michigan; researchers have made notable strides by initiating two past clinical trials on progressive supranuclear palsy starting from 2019 alone while they contribute towards ongoing investigation into new possibilities through another current active study focusing upon it once again

While these hospitals may have varying numbers of active or completed PSP trials due to the rarity of the condition itself; their collective efforts highlight how medical professionals across different locations endeavor together towards progress for those affected by this debilitating disorder.Through continuous exploration within such top-tier institutions ,we can hope that advances will be made leading us closer than ever before toward better diagnosis,treatment,and eventually,a cure for Progressive Supranuclear Palsy

Which are the best cities for progressive supranuclear palsy clinical trials?

When it comes to clinical trials for progressive supranuclear palsy, several cities stand out as key locations. Boca Raton in Florida, Rochester in Minnesota, Gainesville in Florida, Las Vegas in Nevada, and La Jolla in California all offer opportunities to participate in research studies for this condition. These cities collectively host a total of 12 active trials investigating various interventions such as TPN-101 at different doses, antisense oligonucleotide therapy, and F-18 AV 1451. If you are seeking to contribute to the advancement of knowledge about progressive supranuclear palsy or explore potential treatment options through clinical trials, these cities provide promising avenues for participation.

Which are the top treatments for progressive supranuclear palsy being explored in clinical trials?

Exciting progress is being made in clinical trials for progressive supranuclear palsy (PSP), with several top treatments showing promise. Topping the list is TPN-101, a drug currently undergoing active trials for PSP. Alongside it, antisense oligonucleotide therapy and repetitive transcranial magnetic stimulation (rTMS) are also being explored as potential treatment options. Additionally, F-18 AV 1451 has shown great potential since its first listing in 2015. These breakthrough therapies offer hope to individuals living with PSP and may pave the way for new advancements in tackling this challenging neurodegenerative disorder.

What are the most recent clinical trials for progressive supranuclear palsy?

Recent clinical trials offer hope for individuals with progressive supranuclear palsy, a challenging neurodegenerative disorder. One trial focuses on TPN-101, an investigational treatment administered at a dosage of 100 mg per day. In another study, researchers are exploring the potential of antisense oligonucleotide therapy to address the symptoms and progression of this condition. Additionally, a Phase 4 trial investigates the effectiveness of using Zolpidem to manage certain aspects associated with progressive supranuclear palsy. These ongoing studies pave the way for advancements in understanding and treating this complex disease, offering new possibilities for patients and their families.

What progressive supranuclear palsy clinical trials were recently completed?

Recently completed clinical trials for progressive supranuclear palsy (PSP) have made significant contributions to our understanding and potential treatment options for this neurodegenerative disorder. One such trial examined the efficacy of a new drug, with promising results reported in October 2021. Another trial focused on evaluating a non-pharmacological intervention and concluded in September 2021. Additionally, an innovative gene therapy study was successfully completed earlier this year in January 2021. These advancements mark important milestones in PSP research, offering hope for improved therapies that may alleviate symptoms and enhance the quality of life for patients affected by this challenging condition.